Organisation paid for research Program year 2025 Source: CMS Open Payments

Hope Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$322,809

26 payments

Through program year 2025, Hope Clinical Research LLC is reported as receiving $322,809 in research payments, across 26 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $58,267 3
2024 Research $40,070 3
2023 Research $11,020 3
2021 Research $1,275 2
2020 Research $925 1
2019 Research $211,253 14

Breakdown

Who paid Research payments · program years 2019–2025
  1. Ironwood Pharmaceuticals, Inc $185,701 4 payments
  2. Amgen Inc. $110,182 11 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $11,626 2 payments
  4. AstraZeneca Pharmaceuticals LP $11,190 1 payment
  5. Boehringer Ingelheim France S.A.S. $2,538 1 payment
  6. Sumitomo Pharma America, Inc. $1,375 1 payment
  7. Boehringer Ingelheim International GmbH $197 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. C3718-302 $185,701 4 payments
  2. A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM $42,746 1 payment
  3. ASCEND P3 AD Extension $30,235 2 payments
  4. Phase II in lupus nephritis $14,164 3 payments
  5. A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) $12,520 1 payment
  6. A Phase 3 Randomized Double Blind Placebo Controlled Study Evaluating the Safety and Efficacy of Roxadustat AZD9941 for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis $11,190 1 payment
  7. VOYAGER P3 AD Vaccine Study $9,835 1 payment
  8. P3 AD Extension $5,905 1 payment
  9. P3 AD Vaccine Study $3,740 1 payment
  10. A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) $3,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record